tbuckley/cabot-search huggingface dataset:
PTH-178 <i>In vitro</i>and<i>ex vivo</i>models of topical alginate protection of human oesophageal epithelium in gastro-oesophageal reflux disease
Authors: F Batista-Lima, C Lee, D Sifrim, P Woodland
Journal: Gut (2015)

<h3>Introduction</h3> Up to 40% of patients with gastro-oesophageal reflux disease remain symptomatic despite PPI therapy. In addition to acid the refluxate contains pepsin and bile acids, which may be important in symptom perception. A topical therapy could protect against all components of the refluxate. A reliable model for testing could be used to screen compounds for clinical evaluation. We aimed to evaluate and compare the topical protective effect of an alginate solution in a cell culture and human biopsy model. <h3>Method</h3> Primary human oesophageal epithelial cells were established into multilayer stratified squamous epithelia using an air-liquid interface technique. After placing in Ussing chambers the apical surface was “protected” with 200 µl of either alginate, viscous control, or was unprotected. After 15 min washing in neutral solution the tissue was exposed to pH 3 + bile acid solution for 30 min and TER change was calculated. Distal human oesophageal biopsies were taken, placed in Ussing chambers and “protected” as above. After 15 min or 60 min washing in neutral solution, change in TER on 30 min exposure to pH 1 + bile acid + pepsin solution was measured. Thickness of a fluorescent-labelled alginate coating on the biopsy luminal surface was measured after 15 min (5 biopsies) and 60 min (5 biopsies) washing in pH 7.4 solution. <h3>Results</h3> Acid-induced change in TER was significantly less in alginate-protected epithelium than in epithelium protected with viscous control or unprotected tissue. This was seen in both the cell culture (–1.2 ± 5.1%, n = 5 vs. –38.4 ± 6.2%, n = 4 vs. –41.9 ± 8.1%, n = 3) and human biopsy models (−2.7 ± 1.8% vs. −15.26 ± 3.7% vs. −21.1 ± 4.4%, all n = 12) after 15 min washing. Statistically significant protection was still seen after 60 min washing (–8.3 ± 2.2% vs. –25.1 ± 4.5% vs. –26.4 ± 5.3%, n = 12). After 15 min washing the mean alginate layer thickness was 5.7 ± 0.3 µm, and was 4.3 ± 0.3 µm after 60 min washing. <h3>Conclusion</h3> Alginate topical protection of human oesophageal epithelium against acid-injury is demonstrated in both cell culture and human biopsy models. Epithelial adherence persists for up to 60 min. Topical alginate mucosal protection may be promising as an add-on/alternative therapy for gastro-oesophageal reflux disease. Since the cell culture model was able to reproduce <i>ex vivo</i>biopsy results, it could be an effective tool to screen candidate products prior to clinical evaluation. <h3>Disclosure of interest</h3> F. Batista-Lima: None Declared, C. Lee: None Declared, D. Sifrim Grant/ Research Support from: Research grant from Reckitt-Benckiser, P. Woodland: None Declared.
How Depressed Mood May Develop After Viral Infection
Authors: Tracy Hampton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myocardial Glycogen in the Fetus, Infant and child
Authors: B WITTELS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The other CHOP.
Authors: C G Moertel
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.3.337 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3819803 The other CHOP. C G MoertelxC G MoertelSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.3.337 PDF "The other CHOP.." Journal of Clinical Oncology, 5(3), pp. 337–338© 1987 by American Society of Clinical Oncology
Pityriasis Versicolor in Children.
Authors: I. Martin-Scott.
Journal: British Journal of Dermatology (1964)

Journal Article Pityriasis Versicolor in Children. Get access I. Martin‐Scott. I. Martin‐Scott. London Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 76, Issue 4, 1 April 1964, Page 199, https://doi.org/10.1111/j.1365-2133.1964.tb14507.x Published: 01 April 1964
Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer
Authors: Andrew H. Ko, Christopher H. Crane
Journal: Journal of the National Comprehensive Cancer Network (2010)

It is well established that the development of distant metastatic disease represents the dominant pattern of tumor recurrence/progression among patients with operable and locally advanced pancreatic cancer. However, the contribution of localized or locoregional tumor burden to pancreatic cancer-associated morbidity and mortality may be underappreciated, and therefore balancing competing considerations of systemic versus local disease control becomes important in therapeutic decision-making. The role of local therapies, particularly radiation therapy, has remained somewhat controversial in this disease context. Several phase II and III trials have sought to address the relative importance and role of radiation in both the localized and locally advanced settings, including the sequencing of this modality relative to systemic therapy and its optimal means of administration. However, differences and limitations in study design have produced mixed results, particularly in terms of the contribution of radiation to overall survival benefit. An emerging paradigm that makes conceptual sense and remains the subject of active investigation is to start with a defined period of systemic treatment, thus limiting radiation to the subset of patients who do not manifest with metastatic disease during initial therapy and are therefore most likely to benefit from local control.
Prenatal Genetic Diagnosis
Authors: Aubrey Milunsky, John W. Littlefield, Julian N. Kanfer, Edwin H. Kolodny, Vivian E. Shih, Leonard Atkins
Journal: New England Journal of Medicine (1970)

Glycogen-Storage DiseasesIn patients with Type II glycogenosis (Pompe's disease) alpha-1, 4-glucosidase activity is deficient in the liver,50 leukocytes and cultured fibroblasts.107,108 This enzyme has also been demonstrated in cultivated and noncultivated amniotic-fluid cells.109 Nadler and Messina109 and Cox et al.110 have reported the prenatal diagnosis of this disease in three cases. They demonstrated a deficiency of alpha-1, 4-glucosidase activity in cultured amniotic-fluid cells from known maternal heterozygotes. Alpha-1, 4-glucosidase is present in normal amniotic fluid, which can therefore be assayed directly for diagnostic purposes. Cox et al.110 pointed out that in this disorder, bloody contamination of amniotic fluid could . . .
FRI0275 Long-Term Survival and Baseline Prognostic Factors in a Wide Series of Patients with AAV from Spain. Usefulness of Prognostic Scores (Revas Study)
Authors: R. Solans-Laqué, M. Rodriguez-Carballeira, G. Fraile, M.J. Castillo, J. Rios, L. Saez, X. Solanich, L. Caminal, J. Oristrell, F. Pasquau, E. Fonseca, J. Calleja, M. Zamora, P. Fanlo, M. Abdilla, I. Garcia, B. Sopeña, M. Lopez-Dupla, A. Pérez, B. Frutos
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> AAV are still related to a high morbidity and mortality in spite of therapeutic advances.To identify factors present at diagnosis that are associated with a worse prognosis, it is essential to tailoring the treatment <h3>Objectives</h3> To describe the long-term survival rate and possible prognostic factors at presentation in a large cohort of patients with AAV from Spain, and compare BVAS a FFS prognostic scores <h3>Methods</h3> Multicenter retrospective-longitudinal study that included patients diagnosed with AAV between Jan1995 and Dec 2013 in 20 Hospitals from Spain (REVAS Study). Statistical analysis was done using SPSS vs19. <h3>Results</h3> Four hundred and fifty patients (50.4% men) were included: 184 GPA,167 MPA and 99 EGPA. ANCA were positive in 86.4% of cases:36.2% C-ANCA, 50.2% P-ANCA. Mean age at diagnosis was 55.6±17.4 y. Mean time to diagnosis was 4 weeks (0-240). The most frequent symptoms at diagnosis were fever (53%),constitutional symptoms (51%), arthralgia (53%), hypertension (29%), purpura (20%) and hemoptisis (19%). Renal failure was present in 47% of cases, lung involvement in 45.3%, pulmonary-renal syndrome in 16%,and cardiac involvement in 11%. Sensory peripheral neuropathy was detected in 16% of cases,mononeuritis multiplex in 28% and CVA in 4.5%. ENT was observed in 35% and eye involvement in 20%. All patients received oral glucocorticoids. Cyclophosphamide was given to 286 patients (45.3%IV and 38% oral). Dialysis was required in 19% of cases and plasma exchange in 7%. During the follow-up 40% of patients suffered bacterial infections, 10% sepsis 14.6% opportunistic infections and 6% neoplasms. One hundred and twenty-nine (28.7%) died: 74 (44.3%) with MPA,41 (22.3%) with WG and 14 (14%) with CSS. Mean survival was 82.5 months (0-307). Mortality was significantly higher in MPA (p=0.00). Poor prognosis factors at diagnosis were renal failure (HR 1.6),cardiac failure (HR 3.3),bacterial infections (HR 1.8)and age at diagnosis &gt;65y (HR 4.1).BVAS and FFS were significantly associated with outcome. <h3>Conclusions</h3> Among AAV, PAM is associated with the worse prognosis. Renal and cardiac failure, bacterial infections, and age at diagnosis &gt;65y, are associated with a poor clinical outcome. Three of these factors are included in the revised version of FFS, supporting its usefulness as a prognostic score. <h3>References</h3> Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. ARD 2011;70:488–94. Guillevin L, C,Seror R,et al.The Five-Factor Score Revisited Assessment of Prognoses of Systemic Necrotizing Vasculitides. Medicine 2011;90:19-27. <h3>Disclosure of Interest</h3> None declared
Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).
Authors: Robert A. Figlin, Asim Amin, Arkadiusz Dudek, Theodore Logan, Raymond S. Lance, Jeffrey M. Holzbeierlein, Viraj A. Master, Sumanta Kumar Pal, Alicia H. Gamble, Mark DeBenedette, Irina Y. Tcherepanova, W. Lee Williams, Doug Plessinger, Fred Miesowicz, Charles A. Nicolette
Journal: Journal of Clinical Oncology (2012)

348 Background: AGS-003 is a personalized immunotherapy that employs autologous DCs co-electroporated with the subject’s amplified tumor mRNA and synthetic CD40L RNA. Based on previous results with single agent AGS‐003 and acceptance of TKIs as the standard of care for mRCC, AGS-003 was evaluated in combination with sunitinib as initial treatment for advanced RCC. Progression free survival (PFS) results for the combination have been previously presented and show improvement compared to historical data in unfavorable risk patients treated with sunitinib alone. Methods: AGS-003-006 is an open label phase II study that included subjects with newly diagnosed, metastatic clear cell RCC. Tumor was harvested by nephrectomy or metastasectomy for mRNA. Autologous monocytes were collected by leukapheresis for the production of DCs. Subjects subsequently received sunitinib (4wks on, 2wks off) combined with AGS-003 (every 3wks X 5 doses, then every 12wks) until progression. AGS-003 doses consisted of 1 X 10 7 cells administered by intradermal injection to a single lymph node basin. Response was evaluated per RECIST and subjects followed for PFS and OS. Immune responses were assessed at baseline and after five AGS-003 doses using multiparametric flow cytometry. Results: 25 subjects were enrolled; 21 received treatment. The median PFS from registration for subjects receiving at least one dose of AGS-003 was 11.9 months. For subjects with 1–2 MSKCC risk factors (intermediate risk), PFS = 14.9 months and for subjects with 3–4 MSKCC risk factors (poor risk), PFS = 6.0 months. Median OS from registration has not been reached. Median OS for poor risk subjects = 7.9 months. Median OS for intermediate risk subjects has yet to be reached, but will exceed 28.3+ months. Conclusions: AGS-003 is well tolerated with no immunotherapy-related SAEs or grade 3/4 AEs reported. Interim data indicate that AGS-003 in combination with sunitinib yields a median OS higher than that reported for sunitinib alone in unfavorable risk subjects. Updated OS and immune response correlates will be presented. These results support the ongoing, randomized phase III ADAPT study.
Current and emerging models of residential psychiatric treatment, with special reference to the California situation
Authors: R M Atkinson
Journal: American Journal of Psychiatry (1975)

The author reviews the steps that have led to the progressive deemphasis of psychiatric hospitalization in California and surveys the empirical basis for rejecting the usefulness of hospitalization. He discusses the four alternative residential models that have emerged in California as substitutes for state mental hospitals--general hospital psychiatric units, board and care homes, private psychiatric facilities available through vendor contracts, and convalescent hospitals. The author also touches briefly upon some important problems, including the possible fate of public general hospital psychiatric units, community mental health services, and the commitment law in California.
The dexamethasone suppression test with mildly to moderately depressed outpatients
Authors: J G Rabkin, F M Quitkin, J W Stewart, P J McGrath, J Puig-Antich
Journal: American Journal of Psychiatry (1983)

In 66 depressed outpatients given the 1-mg dexamethasone suppression test (DST), the overall rate of nonsuppression was 14%. There was little difference in the rates for patients with endogenous and nonendogenous depression and no overlap between baseline cortisol hypersecretion and DST abnormality.
Porphyria cutanea tarda
Authors: M E Grossman
Journal: New England Journal of Medicine (1994)

Figure 1. Porphyria cutanea tarda. Water-soluble porphyrins from a liver-biopsy specimen from a patient with porphyria cutanea tarda show pink fluorescence under a Wood's light (405 nm). The biopsy specimen (short arrow) was preserved in saline solution to prevent desiccation and then transferred to a piece of gauze. Drops of saline containing fluorescing water-soluble porphyrins, including uroporphyrin (8-carboxylporphyrin) and 7-carboxylporphyrin, stain the gauze pink around the specimen and elsewhere (long arrow).
AB1211-HPR Health-Related Quality of Life and its Predictors Among Patients with Rheumatoid Arthritis
Authors: S. Wan, H.-G. He, A. Mak, M. Lahiri, N. Luo, P.P. Cheung, W. Wang
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis is a chronic, progressive and debilitative inflammatory autoimmune disease that exerts negative impact on patients9 physical and psychosocial wellbeing.<sup>1</sup> This leads to an overall reduction of their quality of life.<sup>2</sup> A review of the literature shows that no any study has examined the predictors of health-related quality of life (HRQoL) among a wide range of relevant and interrelated factors. <h3>Objectives</h3> To explore the HRQoL and its predictors among patients with RA in Singapore. <h3>Methods</h3> This was a cross-sectional, descriptive, correlational study. A convenience sample of 108 outpatients aged 21 and above, diagnosed with RA for more than six months was recruited from a tertiary public hospital in Singapore from October 2013 to February 2014. Outcomes were measured by valid and reliable instruments of the European Quality of Life-5 dimensions, Morisky Medication Adherence Scale-8 items, Medical Outcomes Study Social Support Survey, Impact of Rheumatic Diseases on General health and Lifestyle pain-subscale, Numerical Rating Scale, Health Assessment Questionnaire-Disability Index and the Hospital Anxiety and Depression Scale. Descriptive statistics, independent t-tests, analysis of variance, Pearson Product-Moment correlation coefficient and multiple linear regression were used to analyse the data using the IBM SPSS version 21.0 for Windows (IBM Corp., Armonk, NY). <h3>Results</h3> Participants had moderate HRQoL. Statistically significant difference of HRQoL was found between living status subgroups. HRQoL was positively correlated with medication adherence and overall social support. HRQoL was negatively correlated with pain, functional disability, anxiety and depression. Pain, functional disability and depression were main predictors of HRQoL among patients with RA. <h3>Conclusions</h3> This study highlights the impact of pain, functional disability and depression on HRQoL of patients with RA. Healthcare professionals should pay more attention to improving patients9 psychological wellbeing, in addition to manage their physical symptoms, such as pain and functional ability. This study implied a need for future interventions to enhance the HRQoL of patients with rheumatoid arthritis by considering the main predictors of HRQoL. <h3>References</h3> Morris, A., Yelin, E. H., Wong, B., &amp; Katz, P. P. (2008). Patterns of psychosocial risk and long-term outcomes in rheumatoid arthritis. Psychology, Health &amp; Medicine, 13(5), 529-544. doi: 10.1080/13548500801927113. Sangha, O. (2000). Epidemiology of rheumatic disease. Rheumatology (Oxford), 39(Suppl. 2), 3-12. <h3>Acknowledgements</h3> We appreciate the support from all participants. <h3>Disclosure of Interest</h3> None declared
A Case of a Man With Isolated Breast Metastasis From Lung Adenocarcinoma Incidentally Detected by FDG PET/CT
Authors: Seval Erhamamci, Mehmet Reyhan, Tuba Canpolat, Gul Nihal Nursal, Ali Fuat Yapar
Journal: Clinical Nuclear Medicine (2015)

Breast metastases from an extramammary primary tumor are very rare, particularly in men. In this study, we present a case of a 74-year-old man with isolated breast metastasis from lung adenocarcinoma as an incidental finding on PET/CT and diagnosed concomitantly with the primary tumor. Detection of isolated incidental metastatic lesions in the breast on PET/CT imaging has a significant clinical impact on patients with known malignant disease due to change of disease stage, management, and also treatment method.
Syphilis Screening in the 21st Century
Authors: Kenneth A. Katz
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal